Literature DB >> 20126474

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

Adam Clauss1, Vivian Ng, Joyce Liu, Huiying Piao, Moises Russo, Natalie Vena, Qing Sheng, Michelle S Hirsch, Tomas Bonome, Ursula Matulonis, Azra H Ligon, Michael J Birrer, Ronny Drapkin.   

Abstract

Ovarian cancer is a leading cause of cancer mortality in women. The aim of this study was to elucidate whether whey acidic protein (WAP) genes on chromosome 20q13.12, a region frequently amplified in this cancer, are expressed in serous carcinoma, the most common form of the disease. Herein, we report that a trio of WAP genes (HE4, SLPI, and Elafin) is overexpressed and secreted by serous ovarian carcinomas. To our knowledge, this is the first report linking Elafin to ovarian cancer. Fluorescence in situ hybridization analysis of primary tumors demonstrates genomic gains of the Elafin locus in a majority of cases. In addition, a combination of peptidomimetics, RNA interference, and chromatin immunoprecipitation experiments shows that Elafin expression can be transcriptionally upregulated by inflammatory cytokines through activation of the nuclear factor kappaB pathway. Importantly, using a clinically annotated tissue microarray composed of late-stage, high-grade serous ovarian carcinomas, we show that Elafin expression correlates with poor overall survival. These results, combined with our observation that Elafin is secreted by ovarian tumors and is minimally expressed in normal tissues, suggest that Elafin may serve as a determinant of poor survival in this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20126474      PMCID: PMC2814354          DOI: 10.1593/neo.91542

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  46 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 2.  [Off-pump coronary artery bypass grafting and other minimally invasive techniques].

Authors:  José Cuenca; César Bonome
Journal:  Rev Esp Cardiol       Date:  2005-11       Impact factor: 4.753

3.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors.

Authors:  C Kirchhoff; I Habben; R Ivell; N Krull
Journal:  Biol Reprod       Date:  1991-08       Impact factor: 4.285

4.  Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.

Authors:  Sami Tsukishiro; Nobuhiro Suzumori; Hiroshi Nishikawa; Atsushi Arakawa; Kaoru Suzumori
Journal:  Gynecol Oncol       Date:  2005-02       Impact factor: 5.482

Review 5.  Proteins with whey-acidic-protein motifs and cancer.

Authors:  Dominique Bouchard; Dany Morisset; Yves Bourbonnais; Guy M Tremblay
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

6.  Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues.

Authors:  Daniela Cimino; Luca Fuso; Christian Sfiligoi; Nicoletta Biglia; Riccardo Ponzone; Furio Maggiorotto; Giandomenico Russo; Luigi Cicatiello; Alessandro Weisz; Daniela Taverna; Piero Sismondi; Michele De Bortoli
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

7.  Genetic analysis of benign, low-grade, and high-grade ovarian tumors.

Authors:  H Iwabuchi; M Sakamoto; H Sakunaga; Y Y Ma; M L Carcangiu; D Pinkel; T L Yang-Feng; J W Gray
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

8.  Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.

Authors:  Ahlame Saidi; Sophie Javerzat; Akeila Bellahcène; John De Vos; Lorenzo Bello; Vincent Castronovo; Manuel Deprez; Hugues Loiseau; Andreas Bikfalvi; Martin Hagedorn
Journal:  Int J Cancer       Date:  2008-05-15       Impact factor: 7.396

9.  Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.

Authors:  J M Sallenave; J Shulmann; J Crossley; M Jordana; J Gauldie
Journal:  Am J Respir Cell Mol Biol       Date:  1994-12       Impact factor: 6.914

10.  The gene of the protease inhibitor SKALP/elafin is a member of the REST gene family.

Authors:  A Lundwall; M Ulvsback
Journal:  Biochem Biophys Res Commun       Date:  1996-04-16       Impact factor: 3.575

View more
  39 in total

1.  Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.

Authors:  Samantha Russell; Mark Duquette; Joyce Liu; Ronny Drapkin; Jack Lawler; Jim Petrik
Journal:  FASEB J       Date:  2014-11-13       Impact factor: 5.191

2.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 3.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

4.  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Authors:  Rachel A Davidowitz; Laura M Selfors; Marcin P Iwanicki; Kevin M Elias; Alison Karst; Huiying Piao; Tan A Ince; Michael G Drage; Judy Dering; Gottfried E Konecny; Ursula Matulonis; Gordon B Mills; Dennis J Slamon; Ronny Drapkin; Joan S Brugge
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

5.  Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

Authors:  Huafeng Wei; Karl Erik Hellström; Ingegerd Hellström
Journal:  Gynecol Oncol       Date:  2012-03-16       Impact factor: 5.482

6.  Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.

Authors:  Chang K Sung; Dawei Li; Erik Andrews; Ronny Drapkin; Thomas Benjamin
Journal:  Mol Oncol       Date:  2012-12-12       Impact factor: 6.603

7.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

8.  Transcriptional and post-translational regulation of the quiescence factor and putative tumor suppressor p150(Sal2).

Authors:  Chang K Sung; Jean Dahl; Hyungshin Yim; Scott Rodig; Thomas L Benjamin
Journal:  FASEB J       Date:  2011-01-12       Impact factor: 5.191

9.  Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.

Authors:  Zhigang C Wang; Nicolai Juul Birkbak; Aedín C Culhane; Ronny Drapkin; Aquila Fatima; Ruiyang Tian; Matthew Schwede; Kathryn Alsop; Kathryn E Daniels; Huiying Piao; Joyce Liu; Dariush Etemadmoghadam; Alexander Miron; Helga B Salvesen; Gillian Mitchell; Anna DeFazio; John Quackenbush; Ross S Berkowitz; J Dirk Iglehart; David D L Bowtell; Ursula A Matulonis
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

10.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.